The parametric response map is an imaging biomarker for early cancer treatment outcome

Nature Medicine

Volumn 15, Issue 5, 2009, Pages 572-576

  Galbán, Craig J ^a   Chenevert, Thomas L ^a   Meyer, Charles R ^a   Tsien, Christina ^b   Lawrence, Theodore S ^b   Hamstra, Daniel A ^b   Junck, Larry ^b   Sundgren, Pia C ^a   Johnson, Timothy D ^a   Ross, David J ^b   Rehemtulla, Alnawaz ^a,b   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GADOLINIUM PENTETATE; TEMOZOLOMIDE;

ACCURACY; ADULT; AGE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; GLIOMA; HUMAN; IMAGE ANALYSIS; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PARAMETRIC RESPONSE MAP; PERFUSION WEIGHTED IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

BLOOD VOLUME; BRAIN MAPPING; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; GLIOMA; HEMODYNAMICS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; ROC CURVE; SURVIVAL RATE; SURVIVORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67349249839     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1919     Document Type: Article

References (32)

1. O'Connor, J.P., Jackson, A., Parker, GJ. & Jayson, G.C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. r. J. Cancer 96, 189-195 (2007).
2. Zahra, M.A., Hollingsworth, K.G., Sala, E., Lomas, D.J. & Tan, L.T. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol. 8, 63-74 (2007).
3. Cao, Y. et al. Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int. J. Radiat. Oncol. Biol. Phys. 64, 876-885 (2006).
4. østergaard, L, Weisskoff, R.M., Chesler, D.A., Gyldensted, C. & Rosen, B.R. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn. Reson. Med. 36, 715-725 (1996).
5. Rosen, B.R., Belliveau, J.W., Vevea, J.M. & Brady, T.J. Perfusion imaging with NMR contrast agents. Magn. Reson. Med. 14, 249-265 (1990).
6. Brix, G. etal. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn. Reson. Med. 52, 420-429 (2004).
7. Hoffmann, U., Brix, G., Knopp, M.V., Hess, T. & Lorenz, W.J. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn. Reson. Med. 33, 506-514 (1995).
8. Tofts, P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging 7, 91-101 (1997).
9. Degani, H., Gusis, V., Weinstein, D., Fields, S. &Strano, S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat. Med. 3, 780-782 (1997).
10. Galbraith, S.M. et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed. 15, 132-142 (2002).
11. Hylton, N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 24, 3293-3298 (2006).
12. Thomas, A.L. et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 23, 4162-4171 (2005).
13. Xiong, H.Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459-466 (2004).
14. Tofts, P.S. et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 10, 223-232 (1999).
15. Eyal, E. & Degani, H. Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI. NMR Biomed. 22, 40-53 (2009).
16. Kiessling, F., Morgenstern, B. & Zhang, C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr. Med. Chem. 14, 77-91 (2007).
17. Law, M. et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247, 490-498 (2008).
18. Law, M.,Young, R., Babb,J., Pollack, E. & Johnson, G. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am. J. Neuroradiol. 28, 761-766 (2007).
19. Young, R., Babb, J., Law, M., Pollack, E. & Johnson, G. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J. Magn. Reson. Imaging 26, 1053-1063 (2007).
20. Hamstra, D.A. etal. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc. Natl. Acad. Sci. USA 102, 16759-16764 (2005).
21. Lee, K.C. et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9, 1003-1011 (2007).
22. Lee, K.C. et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res. 67, 3524-3528 (2007).
23. Moffat, B.A. et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc. Natl. Acad. Sci. USA 102, 5524-5529 (2005).
24. Moffat, B.A. et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8, 259-267 (2006).
25. Liu, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 23, 5464-5473 (2005).
26. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955-3964 (2003).
27. Mross, K. etal. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 41, 1291-1299 (2005).
28. O'Donnell, A. etal. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br. J. Cancer 93, 876-883 (2005).
29. Rugo, H.S. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474-5483 (2005).
30. Wedam, S.B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769-777 (2006).
31. Chan, J.L. et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J. Clin. Oncol. 20, 1635-1642 (2002).
32. Meyer, C.R. et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med. Image Anal. 1, 195-206 (1997).